A new real-world analysis of more than 90,000 patients with obesity and type 2 diabetes finds metabolic and bariatric surgery costs significantly less than weekly injections of GLP-1 drugs over a two-year period, according to new research presented at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery (ASMBS2026).
Continue Reading this article here
